A Phase 1 interventional study of Vorinostat and Vorinostat in Tumors, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-08-27.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a clinical study to evaluate the safety and pharmacokinetics of an overseas determined maximum tolerated dose (MTD) of MK-0683 (vorinostat) in a Japanese patient population with solid tumors.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 16 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
600 mg daily (300 mg twice daily \[b.i.d.\]) for 3 consecutive days followed by 4 days of rest.
Drug: Vorinostat
400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
Drug: Vorinostat
600 mg daily (300 mg twice daily \[b.i.d.\]) for 3 consecutive days followed by 4 days of rest.
Also known as: MK-0683, Suberoylanilide Hydroxamic Acid (SAHA)
400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
Also known as: MK-0683, Suberoylanilide Hydroxamic Acid (SAHA)
Number of Participants With a Dose Limiting Toxicity (DLT)
Dose Limiting Toxicity = Drug-related side effects that are serious enough to prevent an increase in dose or level of that treatment
Time frame: 21 Days (first cycle)
Area Under the Curve (AUC(0-infinity)) at Day 1 (600 mg and 400 mg)
Area Under Curve (AUC(0-infinity))=Area under the plasma concentration versus time curve (AUC) from time zero to extrapolated infinite time (o- ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). At 600 mg, t=12 hours and at 400 mg, t=24 hours.
Time frame: Day 1 (600 mg and 400 mg)
Area Under the Curve (AUC(0-infinity)) at Day 3 (600 mg)
Area Under Curve (AUC(0-infinity))=Area under the plasma concentration versus time curve (AUC) from time zero to 24 hours. It is obtained from AUC (0 - 12) plus AUC (12 - ∞)
Time frame: Day 3 (600 mg)
Area Under the Curve (AUC(0-infinity) at Day 21 (400 mg)
Area Under Curve (AUC(0-infinity))=Area under the plasma concentration versus time curve (AUC) from time zero to 24 hours. It is obtained from AUC (0 - 24) plus AUC (24 - ∞)
Time frame: Day 21 (400 mg)
Maximum Concentration (Cmax) at Day 1 (600 mg and 400 mg)
Time frame: Day 1 (600 mg and 400 mg)
Maximum Concentration (Cmax) at Day 3 (600 mg)
Time frame: Day 3 (600 mg)
Maximum Concentration (Cmax) at Day 21 (400 mg)
Time frame: Day 21 (400 mg)
Phase I. First participant started on study therapy on 18-Jul-2006. Study was multicenter (total of 3 sites).
| Milestone | Vorinostat 600 mg | Vorinostat 400 mg |
|---|---|---|
| Started | 10 | 6 |
| Completed | 1 | 0 |
| Not completed | 9 | 6 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lack of efficacy | 9 | 4 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Dose Limiting Toxicity = Drug-related side effects that are serious enough to prevent an increase in dose or level of that treatment
| Participants | Vorinostat 600 mg | Vorinostat 400 mg |
|---|---|---|
| Number of Participants With a Dose Limiting Toxicity (DLT) | 0 | 2 |
Area Under Curve (AUC(0-infinity))=Area under the plasma concentration versus time curve (AUC) from time zero to extrapolated infinite time (o- ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). At 600 mg, t=12 hours and at 400 mg, t=24 hours.
| μM·hr | Vorinostat 600 mg | Vorinostat 400 mg |
|---|---|---|
| Area Under the Curve (AUC(0-infinity)) at Day 1 (600 mg and 400 mg) | 3.94 ± 1.56 | 7.75 ± 2.79 |
Area Under Curve (AUC(0-infinity))=Area under the plasma concentration versus time curve (AUC) from time zero to 24 hours. It is obtained from AUC (0 - 12) plus AUC (12 - ∞)
| μM·hr | Vorinostat 600 mg | Vorinostat 400 mg |
|---|---|---|
| Area Under the Curve (AUC(0-infinity)) at Day 3 (600 mg) | 4.15 ± 2.15 | — |
Area Under Curve (AUC(0-infinity))=Area under the plasma concentration versus time curve (AUC) from time zero to 24 hours. It is obtained from AUC (0 - 24) plus AUC (24 - ∞)
| μM·hr | Vorinostat 600 mg | Vorinostat 400 mg |
|---|---|---|
| Area Under the Curve (AUC(0-infinity) at Day 21 (400 mg) | — | 8.3 ± 0.04 |
| μM | Vorinostat 600 mg | Vorinostat 400 mg |
|---|---|---|
| Maximum Concentration (Cmax) at Day 1 (600 mg and 400 mg) | 1.17 ± 0.43 | 1.62 ± 0.52 |
| μM | Vorinostat 600 mg | Vorinostat 400 mg |
|---|---|---|
| Maximum Concentration (Cmax) at Day 3 (600 mg) | 1.32 ± 0.75 | — |
| μM | Vorinostat 600 mg | Vorinostat 400 mg |
|---|---|---|
| Maximum Concentration (Cmax) at Day 21 (400 mg) | — | 2.04 ± 0.78 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vorinostat 600 mg | — | 4/10 (40%) | 10/10 (100%) |
| Vorinostat 400 mg | — | 0/6 (0%) | 6/6 (100%) |
| Event | Vorinostat 600 mg | Vorinostat 400 mg |
|---|---|---|
| ABDOMINAL PAINGastrointestinal disorders | 2/10 | 0/6 |
| DIARRHOEAGastrointestinal disorders | 1/10 | 0/6 |
| VOMITINGGastrointestinal disorders | 1/10 | 0/6 |
| DISEASE PROGRESSIONGeneral disorders | 1/10 | 0/6 |
| HYPERBILIRUBINAEMIAHepatobiliary disorders | 1/10 | 0/6 |
| Event | Vorinostat 600 mg | Vorinostat 400 mg |
|---|---|---|
| NAUSEAGastrointestinal disorders | 8/10 | 6/6 |
| PLATELET COUNT DECREASEDInvestigations | 3/10 | 6/6 |
| ANOREXIAMetabolism and nutrition disorders | 9/10 | 6/6 |
| VOMITINGGastrointestinal disorders | 5/10 | 5/6 |
| BLOOD CREATININE INCREASEDInvestigations | 5/10 | 5/6 |
| BLOOD GLUCOSE INCREASEDInvestigations | 6/10 | 5/6 |
| FATIGUEGeneral disorders | 8/10 | 4/6 |
| LYMPHOCYTE COUNT DECREASEDInvestigations | 5/10 | 4/6 |
| CONSTIPATIONGastrointestinal disorders | 6/10 | 1/6 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 6/10 | 3/6 |
| Age, Continuous(years) | Vorinostat 600 mg | Vorinostat 400 mg | Total |
|---|---|---|---|
| Mean | 60.2 ± 8.4 | 53.3 ± 12 | 57.6 ± 10.1 |
| Sex: Female, Male(Participants) | Vorinostat 600 mg | Vorinostat 400 mg | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 8 | 4 | 12 |
| Prior chemotherapy regimens(Number of prior chemotherapy regimens) | Vorinostat 600 mg | Vorinostat 400 mg | Total |
|---|---|---|---|
| Median | 3.5 (2 to 6) | 4.5 (3 to 6) | 4 (2 to 6) |
No study locations are listed for this record.
The record gives a start of Jul 2006, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.
Results were first posted in May 2009, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorinostat